Flash Finance

Alkem Laboratories LimitedALKEMCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹5,050.00
MCap ₹60,380 Cr · P/E 27.6
Alkem Laboratories Limited — Stock analysis & AI research Alkem Laboratories Limited — Multibagger AI analysis Alkem Laboratories Limited — Seasonality — best & worst months Alkem Laboratories Limited — Technical indicators & charts Alkem Laboratories Limited — Technical setup — score, trend, support & resistance Alkem Laboratories Limited — Triple Top pattern broken down ↓ Alkem Laboratories Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Interest Coverage Stocks📋 GARP Stocks (PEG Below 1)📋 Low Debt Stocks📋 Mid Cap Stocks List📋 Quality Stocks 📈 MACD Bearish Crossover📈 New 52-Week Low Stocks📈 20-Day Breakdown Stocks📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹3,740 Cr
Sales · Jun 2026
+10.9% YoY
₹766 Cr
Operating Profit · Jun 2026
+3.6% YoY
20.5%
OPM % · Jun 2026
-6.4% YoY
₹521 Cr
Net Profit · Jun 2026
-21.6% YoY
₹43.49
EPS · Jun 2026
-21.7% YoY

📝 Alkem Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Alkem Laboratories Limited reported revenue of ₹3,740 crore for the quarter ended June 2026 (Q1 FY27), up 10.9% from ₹3,371 crore in the same quarter last year, and up 3.8% sequentially over the March 2026 quarter.

Net profit fell 21.6% year-on-year to ₹521 crore, from ₹664 crore. Earnings per share (EPS) came in at ₹43.49.

Operating profit stood at ₹766 crore — an operating margin (OPM) of 20.5%, compared with 21.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Alkem Laboratories Limited posted revenue of ₹14,712 crore, a growth of 13.5% over FY25, with a net profit of ₹2,330 crore (up 7.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹15,081 crore with a net profit of ₹2,187 crore.

Valuation snapshot

At the current price of ₹5,050.00, ALKEM has a market capitalisation of ₹60,380 crore and a trailing P/E of about 27.6.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 12th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 51.20%, foreign institutional investors (FIIs) 10.15%, domestic institutional investors (DIIs) 21.39%, public shareholders 17.25% of Alkem Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹60,380 Cr
Current Price ?
₹5,050.0
P/E ?
27.61below ind
Industry P/E ?
35.00
P/B ?
4.37
P/S ?
4.00
P/FCF ?
40.91
Enterprise Value ?
₹62,427 Cr
EV/EBITDA ?
20.59
PEG ?
0.86
Earnings Yield ?
4.2%
Dividend Yield ?
0.89%
Profitability & Returns
Sales (TTM) ?
₹15,081 Cr
OPM ?
20.1%
Profit after tax (TTM) ?
₹2,187 Cr
EPS (TTM) ?
₹182.92
ROCE ?
21.0%
ROE ?
15.8%
ROA ?
10.5%
Growth
Sales — latest qtr ?
₹3,740 Cr
PAT — latest qtr ?
₹521 Cr
YoY qtr sales growth ?
10.9%
YoY qtr profit growth ?
-21.6%
Sales growth (3y) ?
8%
Sales growth (5y) ?
11%
Profit growth (3y) ?
32%
Profit growth (5y) ?
9%
Financial Health
Debt ?
₹2,047 Cr
Debt to Equity ?
0.15
Interest Coverage ?
16.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.20%
Change in promoter holding ?
-1.84%
Pledged percentage ?
N/A
Market
Return 3 months ?
-9.2%
Return 6 months ?
-9.5%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 3,0412,9032,9683,4403,3242,9363,0323,4153,3743,1443,3714,0013,7373,6033,740 +10.9% +3.8%
Operating Profit 599353389747708402609753759391739921828517766 +3.6% +48.2%
Other Income 45-346664276120134931461491049065153 +2.5% +135.0%
Interest 272930302527292836283035425447 +55.4% -13.7%
Depreciation 787872747083807985112889495106100 +13.9% -5.5%
Profit Before Tax 539212353648706380619780731396758896781423772 +1.8% +82.5%
Net Profit 45571287620595294545689626306664779636251521 -21.6% +107.6%
EPS 38.035.9423.9851.9049.7624.5545.6057.6052.3425.5855.5663.9953.1919.7843.49 -21.7% +119.9%
OPM % 19.7% 12.2% 13.1% 21.7% 21.3% 13.7% 20.1% 22.0% 22.5% 12.4% 21.9% 23.0% 22.2% 14.3% 20.5% -6.4% +43.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹12,965 Cr ₹14,712 Cr ₹15,081 Cr +13.5%
Operating Profit ₹2,512 Cr ₹3,005 Cr ₹3,032 Cr +19.6%
OPM % 19.38% 20.42% 20.10% +5.4%
NPM % 16.70% 15.84% 14.50% -5.1%
Other Income ₹493 Cr ₹408 Cr ₹411 Cr -17.3%
Depreciation ₹356 Cr ₹383 Cr ₹395 Cr +7.5%
Interest ₹121 Cr ₹161 Cr ₹178 Cr +33.1%
EBIT ₹2,156 Cr ₹2,622 Cr ₹2,637 Cr +21.6%
PBT ₹2,527 Cr ₹2,858 Cr ₹2,872 Cr +13.1%
Tax — ₹116 Cr ₹367 Cr —
Net Profit ₹2,166 Cr ₹2,330 Cr ₹2,187 Cr +7.6%
EPS ₹181.12 ₹192.52 ₹180.45 +6.3%
Material Cost — ₹1,377 Cr ₹2,653 Cr —
Employee Cost — ₹710 Cr ₹1,519 Cr —
Extraordinary Items — ₹-53 Cr ₹-53 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CWIP 323159548138 -74.8%
Equity Capital 24242424 +0.0%
Reserves 9,02110,28811,96113,796 +15.3%
Borrowings 1,3971,4181,3812,047 +48.2%
Other Liabilities 3,3153,8444,3255,006 +15.7%
Total Liabilities 13,75715,57517,69120,873 +18.0%
Fixed Assets 2,6832,8732,8524,015 +40.8%
Investments 6224841,8461,869 +1.2%
Other Assets 10,12912,06012,44514,851 +19.3%
Total Assets 13,75715,57517,69120,873 +18.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,6821,9481,9131,963 +2.6%
Cash from Investing Activity 120-1,011-1,288-1,667 -29.4%
Cash from Financing Activity -1,761-1,145-811-503 +38.0%
Net Cash Flow 42-207-186-208 -11.8%
Free Cash Flow 1,4531,7611,2781,476 +15.5%
CFO/OP 121%105%96%86% -10.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 67656974 +7.2%
Inventory Days 194197224239 +6.7%
Days Payable 87129141161 +14.2%
Cash Conversion Cycle 174132152152 +0.0%
Working Capital Days 66135124141 +13.7%
ROCE % 14%20%20%21% +5.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 53.04%51.20%51.20%51.20% +0.0%
FIIs 9.11%9.47%9.97%10.15% +1.8%
DIIs 21.80%21.93%21.54%21.39% -0.7%
Public 16.05%17.39%17.30%17.25% -0.3%
No. of Shareholders 79,74067,19664,53662,835 -2.6%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Alkem Laboratories Limited's revenue in Q1 FY27?
Alkem Laboratories Limited reported revenue of ₹3,740 crore for the quarter ended June 2026 (Q1 FY27), up 10.9% from ₹3,371 crore in the same quarter last year, and up 3.8% sequentially over the March 2026 quarter.
What was Alkem Laboratories Limited's net profit in Q1 FY27?
Net profit fell 21.6% year-on-year to ₹521 crore, from ₹664 crore. Earnings per share (EPS) came in at ₹43.49.
What is ALKEM's market capitalisation and P/E ratio?
At the current price of ₹5,050.00, ALKEM has a market capitalisation of ₹60,380 crore and a trailing P/E of about 27.6.
Who owns Alkem Laboratories Limited? (shareholding pattern)
As of Mar 2026, promoters held 51.20%, foreign institutional investors (FIIs) 10.15%, domestic institutional investors (DIIs) 21.39%, public shareholders 17.25% of Alkem Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI